Bruce Keyt - IGM Biosciences Chief Officer
| IGMS Stock | USD 9.40 0.51 5.74% |
Insider
Bruce Keyt is Chief Officer of IGM Biosciences
| Age | 71 |
| Address | 325 East Middlefield Road, Mountain View, CA, United States, 94043 |
| Phone | 650 965 7873 |
| Web | https://igmbio.com |
Bruce Keyt Latest Insider Activity
Tracking and analyzing the buying and selling activities of Bruce Keyt against IGM Biosciences stock is an integral part of due diligence when investing in IGM Biosciences. Bruce Keyt insider activity provides valuable insight into whether IGM Biosciences is net buyers or sellers over its current business cycle. Note, IGM Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell IGM Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Bruce Keyt over three weeks ago Acquisition by Bruce Keyt of 24019 shares of IGM Biosciences subject to Rule 16b-3 | ||
Bruce Keyt over six months ago Disposition of 1844 shares by Bruce Keyt of IGM Biosciences at 10.1705 subject to Rule 16b-3 |
IGM Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.3738) % which means that it has lost $0.3738 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3211) %, meaning that it created substantial loss on money invested by shareholders. IGM Biosciences' management efficiency ratios could be used to measure how well IGM Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.61 in 2024. Return On Capital Employed is likely to drop to -0.73 in 2024. At this time, IGM Biosciences' Other Assets are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 10 M in 2024, whereas Total Assets are likely to drop slightly above 300.2 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| CPA CPA | Stoke Therapeutics | 63 | |
| Sergey MD | Black Diamond Therapeutics | 55 | |
| Randi MD | Werewolf Therapeutics | 68 | |
| Steve Andre | Cullinan Oncology LLC | N/A | |
| Frank McCormick | Avidity Biosciences | 74 | |
| Chandra Lovejoy | Erasca Inc | 53 | |
| MBA MD | Ikena Oncology | 59 | |
| MBA MD | Cullinan Oncology LLC | 51 | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| David MD | Passage Bio | N/A | |
| Simona King | Passage Bio | 52 | |
| Jennifer Schroeder | Ikena Oncology | N/A | |
| Ajim CFA | Monte Rosa Therapeutics | 47 | |
| Joan Wood | Stoke Therapeutics | N/A | |
| Walter Reiher | Revolution Medicines | N/A | |
| Dawn Giangiulio | Design Therapeutics | N/A | |
| Michelle Zhang | Ikena Oncology | N/A | |
| FACC MD | Stoke Therapeutics | 61 | |
| Melanie Morrison | Black Diamond Therapeutics | 49 | |
| Corinne Savill | Cullinan Oncology LLC | 65 | |
| Eric Rojas | Stoke Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.32 | ||||
| Return On Asset | -0.37 |
IGM Biosciences Leadership Team
Elected by the shareholders, the IGM Biosciences' board of directors comprises two types of representatives: IGM Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IGM. The board's role is to monitor IGM Biosciences' management team and ensure that shareholders' interests are well served. IGM Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IGM Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| TS Harigopal, Senior Operations | ||
| Faraz Siddiqui, Senior Operations | ||
| Angus Sinclair, Senior ImmunoOncology | ||
| Elizabeth JD, Senior Property | ||
| Elaine Sapinoso, Senior Quality | ||
| Misbah CPA, Chief Officer | ||
| Lisa Decker, Chief Officer | ||
| Paul JD, Senior Affairs | ||
| Steven Weber, Corporate VP | ||
| Shinyu MD, Consultant | ||
| Bruce Keyt, Chief Officer | ||
| Fred JD, President CEO | ||
| Suzette Tauber, Chief Officer | ||
| Misbah Tahir, Chief Officer | ||
| Paul Graffagnino, Senior Affairs | ||
| FACP MD, Chief Officer | ||
| Marvin Peterson, Executive Manufacturing | ||
| Mary MD, President Unit |
IGM Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IGM Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.32 | ||||
| Return On Asset | -0.37 | ||||
| Operating Margin | (124.78) % | ||||
| Current Valuation | 355.71 M | ||||
| Shares Outstanding | 34.08 M | ||||
| Shares Owned By Insiders | 35.04 % | ||||
| Shares Owned By Institutions | 63.98 % | ||||
| Number Of Shares Shorted | 3.37 M | ||||
| Price To Earning | (7.72) X | ||||
| Price To Book | 6.70 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for IGM Stock Analysis
When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.